Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335018 | 0.88 | MAPT (0.54) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL121987 | 0.84 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL1668165 | 0.81 | HCAR3 (0.59) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL2669581 | 0.80 | EPAS1 (0.49) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL6872381 | 0.80 | GAA (0.60) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL12222394 | 0.79 | KMT2A (0.50) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL11341363 | 0.78 | HCAR3 (0.79) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1668970 | 0.78 | EPAS1 (0.59) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL13002357 | 0.77 | AKR1C3 (0.63) | LMNASMN1; SMN2ALDH1A1ATMKMT2A | |
| SCHEMBL9157 | 0.76 | ITGB1 (0.57) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110257210-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2011-10-20 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257210-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | LMNA 4276/4885SMN1; SMN2 3616/4885ALDH1A1 552/4885 |
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | LMNA 4096/4885SMN1; SMN2 1653/4885ALDH1A1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.